DOI: 10.5061/dryad.pc866t1kf
title: Data from: Insulin sensitizers for improving endocrine metabolism in overweight women with PCOS: a network meta-analysis

description: Objective: To evaluate the efficacy of insulin sensitizers on menstrual
 frequency, sex hormone and metabolic parameters in overweight women with
 PCOS. Methods: We searched multiple databases from inception to September
 2019 for RCTs. Network meta-analysis was conducted using multivariate
 random effects method. Results: 14 trials reporting on 619 women were
 included. Compared with metformin, metformin + TZDs was more superior in
 menstrual recovery (WMD 3.68, 95% CrI 1.65 to 8.20), metformin + GLP-1
 receptor agonists was more effective in decreasing AND (WMD -2.53, 95% CrI
 -3.96 to -1.09), both metformin + GLP-1 receptor agonists (WMD 9.22, 95%
 CrI 5.46 to 12.98) and metformin + TZDs (WMD 4.30, 95% CrI 0.78 to 7.82)
 were more effective in increasing SHBG, while TZDs was less effective in
 decreasing BMI (WMD 1.69, 95% CrI 0.72 to 2.66). Compared with GLP-1
 receptor agonists, metformin + GLP-1 receptor agonists was associated with
 higher SHBG (WMD 7.80, 95% CrI 4.75 to 10.85), lower FT (WMD -1.77, 95%
 CrI -3.25 to -0.29), lower AND (WMD -2.70, 95% CrI -3.91 to -1.50) and
 lower FG (WMD -0.41, 95% CrI -0.73 to -0.08). Conclusion: For overweight
 women with PCOS, both metformin combined with GLP-1 receptor agonists and
 metformin combined with TZDs appear superior to monotherapy in improving
 hyperandrogenemia. Metformin combined with TZDs could be particularly
 effective in promoting the recovery of menstruation. Metformin combined
 with GLP-1 receptor agonists has additional advantage in improving fasting
 glucose when compared with GLP-1 receptor agonists alone. TZDs is inferior
 to metformin in decreasing BMI.
description: FIGURE S1.
 Funnel plot for the improvement of menstrual frequency
 (a) FIGURE S2. Funnel
 plot for the improvement of menstrual frequency (b)
 FIGURE S3.
 Funnel plot for the improvement of TT (total
 testosterone) FIGURE S4. Funnel
 plot for the improvement of FT (free testosterone)
 FIGURE S5.
 Funnel plot for the improvement of SHBG (sex hormone binding
 globulin) FIGURE S6. Funnel
 plot for the improvement of AND (androstenedione)
 FIGURE S7.
 Funnel plot for the improvement of FG (fasting
 glucose) FIGURE S8. Funnel
 plot for the improvement of FINS (fasting insulin)
 FIGURE S9.
 Funnel plot for the improvement of BMI (body mass
 index) FIGURE S10. Funnel
 plot for the improvement of WC (waist
 circumference) FIGURE S11. Forest
 plot for the improvement of menstrual frequency (a)
 FIGURE S12.
 Forest plot for the improvement of menstrual frequency
 (b) FIGURE S13. Forest
 plot for the improvement of TT (total testosterone)
 FIGURE S14.
 Forest plot for the improvement of FT (free testosterone) 
 FIGURE S15. Forest
 plot for the improvement of SHBG (sex hormone binding globulin) 
 FIGURE S16. Forest
 plot for the improvement of AND (androstenedione)
 FIGURE S17.
 Forest plot for the improvement of FG (fasting glucose) 
 FIGURE S18. Forest
 plot for the improvement of FINS (fasting insulin)
 FIGURE S19.
 Forest plot for the improvement of BMI (body mass
 index) FIGURE S20. Forest
 plot for the improvement of WC (waist
 circumference)